Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.

PropertyValue
has major subject area list Aminopyridines; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Morpholines; Ovarian Neoplasms; Phthalazines; Piperazines

Search Criteria
  • BRCA1 Protein